146 related articles for article (PubMed ID: 38205538)
1. Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients.
Khwaja J; Ravichandran S; Bomsztyk J; Cohen O; Foard D; Martinez-Naharro A; Venneri L; Fontana M; Hawkins PN; Gillmore J; Lachmann HJ; Mahmood S; Whelan C; Kirkwood AA; Wechalekar A
Haematologica; 2024 May; 109(5):1598-1602. PubMed ID: 38205538
[No Abstract] [Full Text] [Related]
2. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
[TBL] [Abstract][Full Text] [Related]
4. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study.
Wan K; Li W; Sun J; Xu Y; Wang J; Liu H; Dong Y; Cheng W; Zhang Q; Zeng Z; Zhou X; Han Y; Chen Y
Amyloid; 2019 Mar; 26(1):45-51. PubMed ID: 30931628
[TBL] [Abstract][Full Text] [Related]
5. Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management.
Baumgart JV; Stuhlmann-Laeisz C; Hegenbart U; Nattenmüller J; Schönland S; Krüger S; Behrens HM; Röcken C
Virchows Arch; 2018 Nov; 473(5):627-637. PubMed ID: 30136180
[TBL] [Abstract][Full Text] [Related]
6. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
7. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
[TBL] [Abstract][Full Text] [Related]
8. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
Oubari S; Naser E; Papathanasiou M; Luedike P; Hagenacker T; Thimm A; Rischpler C; Kessler L; Kimmich C; Hegenbart U; Schönland S; Rassaf T; Reinhardt HC; Jöckel KH; Dürig J; Dührsen U; Carpinteiro A
Eur J Haematol; 2021 Oct; 107(4):449-457. PubMed ID: 34185342
[TBL] [Abstract][Full Text] [Related]
9. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.
Hwa YL; Gertz MA; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Kapoor P; Zeldenrust SR; Leung N; Hayman SR; Gonsalves WI; Kourelis TV; Warsame R; Go RS; Muchtar E; Hobbs MA; Fonder AL; Russell S; Kyle RA; Rajkumar SV; Dispenzieri A
Leukemia; 2019 May; 33(5):1268-1272. PubMed ID: 30737485
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
[TBL] [Abstract][Full Text] [Related]
11. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.
Sidiqi MH; Aljama MA; Jevremovic D; Morice WG; Timm M; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz M
Haematologica; 2018 Jul; 103(7):1229-1234. PubMed ID: 29674497
[TBL] [Abstract][Full Text] [Related]
12. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.
Milani P; Dispenzieri A; Scott CG; Gertz MA; Perlini S; Mussinelli R; Lacy MQ; Buadi FK; Kumar S; Maurer MS; Merlini G; Hayman SR; Leung N; Dingli D; Klarich KW; Lust JA; Lin Y; Kapoor P; Go RS; Pellikka PA; Hwa YL; Zeldenrust SR; Kyle RA; Rajkumar SV; Grogan M
Circ Cardiovasc Imaging; 2018 May; 11(5):e006588. PubMed ID: 29752392
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis.
Acevedo J; Doros G; Szalat R; Sanchorawala V
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):425-426. PubMed ID: 33622658
[No Abstract] [Full Text] [Related]
15. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.
Rutten KHG; Raymakers RAP; Hazenberg BPC; Nienhuis HLA; Vellenga E; Minnema MC
Amyloid; 2018 Dec; 25(4):227-233. PubMed ID: 30513220
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Boston University staging system in AL amyloidosis.
Tomlinson R; Matigian N; Mollee P
Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007
[No Abstract] [Full Text] [Related]
17. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.
Tandon N; Sidana S; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Kyle RA; Buadi FK; Dingli D; Hayman SR; Fonder AL; Hobbs MA; Gonsalves WI; Kapoor P; Hwa YL; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Kumar SK
Amyloid; 2017 Sep; 24(3):183-188. PubMed ID: 28699793
[TBL] [Abstract][Full Text] [Related]
18. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.
Rezk T; Lachmann HJ; Fontana M; Naharro AM; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Hawkins PN; Gillmore JD
Br J Haematol; 2019 Aug; 186(3):460-470. PubMed ID: 31124579
[TBL] [Abstract][Full Text] [Related]
19. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation.
Havasi A; Stern L; Lo S; Sun F; Sanchorawala V
Am J Hematol; 2016 Oct; 91(10):E458-60. PubMed ID: 27356490
[No Abstract] [Full Text] [Related]
20. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis.
Briasoulis A; Bampatsias D; Petropoulos I; Rempakos A; Patras R; Theodorakakou F; Makris N; Dimopoulos MA; Stamatelopoulos K; Kastritis E
Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):698-707. PubMed ID: 38142437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]